Evidence map›Paper›PMID 28412726›Full record

ArticleOncotarget2017

Inhaled corticosteroids have a protective effect against lung cancer in female patients with chronic obstructive pulmonary disease: a nationwide population-based cohort study.

Shih-Feng Liu, Ho-Chang Kuo, Meng-Chih Lin, Shu-Chen Ho, Mei-Lien Tu, Yu-Mu Chen, Yung-Che Chen, Wen-Feng Fang, Chin-Chou Wang, Guan-Heng Liu

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 4 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 38 citations in OpenAlex.

  1. Chronic Obstructive Pulmonary Disease and Lung Cancer: A Meta-Analysis of Risk Association.International journal of chronic obstructive pulmonary disease · 2025
    Pooled it
  2. Lung cancer occurrence after an episode of tuberculosis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. COPD-Lung Cancer Comorbidity: Mechanistic Insights and Precision Oncology Implications.International journal of chronic obstructive pulmonary disease · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity.International journal of chronic obstructive pulmonary disease
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shih-Feng LiuDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan.
Ho-Chang KuoDepartment of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital Kaohsiung, Taiwan.
Meng-Chih LinDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan.
Shu-Chen HoDepartment of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Mei-Lien TuDepartment of Respiratory Therapy, Kaohsiung Chang Gung Memorial Hospital Kaohsiung, Taiwan.
Yu-Mu ChenDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan.
Yung-Che ChenDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan.
Wen-Feng FangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan.
Chin-Chou WangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung, Taiwan.
Guan-Heng LiuDepartment of Senior High School, Li-Chih Valuable School, Kaohsiung, Taiwan.
Chang Gung University · TWKaohsiung Chang Gung Memorial Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Whether the use of inhaled corticosteroids (ICS) protects patients with chronic obstructive pulmonary disease (COPD) from lung cancer remains undetermined. In this retrospective nationwide population-based cohort study, we extracted data of 13,686 female COPD patients (ICS users, n = 1,290, ICS non-users, n = 12,396) diagnosed between 1997 and 2009 from the Taiwan's National Health Insurance database. These patients were followed-up until 2011, and lung cancer incidence was determined. Cox regression analysis was used to estimate hazard ratios (HRs) for lung cancer incidence. The time to lung cancer diagnosis was significantly different between ICS users and non-users (10.75 vs. 9.68 years, P < 0.001). Per 100,000 person-years, the lung cancer incidence rate was 235.92 for non-users and 158.67 for users [HR = 0.70 (95% confidence interval {CI}: 0.46-1.09)]. After adjusting for patients' age, income, and comorbidities, a cumulative ICS dose > 39.48 mg was significantly associated with a lower risk of lung cancer [ICS users > 39.48 mg, HR = 0.45 (95% CI: 0.21-0.96)]. Age ≥ 60 years, pneumonia, diabetes mellitus, and hypertension decreased lung cancer risk, whereas pulmonary tuberculosis increased the risk. Our results suggest that ICS have a potential role in lung cancer prevention among female COPD patients.

Indexed as

Administration, InhalationAdrenal Cortex HormonesAdultAgedComorbidityFemaleHumansIncidenceLung NeoplasmsMiddle AgedPopulation SurveillancePrevalenceProtective AgentsPulmonary Disease, Chronic ObstructiveSex FactorsSocioeconomic FactorsAdrenal Cortex HormonesProtective Agentschronic obstructive pulmonary diseasehazard ratioincidenceinhaled corticosteroidslung cancer

Identifiers

PMID28412726
PMCPMC5444697
OpenAlexW2587911398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.